KRT19 and neoplasm: The localised KLK6 expression in tumour cells (identified by KRT19) and macrophages (represented by CD68) in the invasive areas underscores the potential for KLK6-targeted inhibitors that interfere with tumour-biological events in a context-dependent manner.